Soleno Therapeutics Files 8-K on Financials
Ticker: SLNO · Form: 8-K · Filed: 2025-03-26T00:00:00.000Z
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
Related Tickers: SLNO
TL;DR
SOLENO THERAPEUTICS (SLNO) filed an 8-K on 3/26/25 updating its financial condition.
AI Summary
On March 26, 2025, Soleno Therapeutics, Inc. filed an 8-K report detailing its financial condition and results of operations. The company, formerly known as Capnia, Inc., is incorporated in Delaware and headquartered in Redwood City, California.
Why It Matters
This filing provides investors with an update on Soleno Therapeutics' financial health and operational performance, which is crucial for evaluating the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any new material events or significant negative news.
Key Players & Entities
- SOLENO THERAPEUTICS INC (company) — Registrant
- Capnia, Inc. (company) — Former company name
- 100 Marine Parkway, Suite 400 Redwood City, CA 94065 (location) — Principal executive offices address
- March 26, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for Soleno Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition, as well as Financial Statements and Exhibits of Soleno Therapeutics, Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 26, 2025.
What was Soleno Therapeutics, Inc.'s former company name?
Soleno Therapeutics, Inc.'s former company name was Capnia, Inc.
Where are Soleno Therapeutics, Inc.'s principal executive offices located?
Soleno Therapeutics, Inc.'s principal executive offices are located at 100 Marine Parkway, Suite 400, Redwood City, CA 94065.
What is the SIC code for Soleno Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Soleno Therapeutics, Inc. is 3845, which corresponds to Electromedical & Electrotherapeutic Apparatus.
From the Filing
0001193125-25-064140.txt : 20250326 0001193125-25-064140.hdr.sgml : 20250326 20250326170033 ACCESSION NUMBER: 0001193125-25-064140 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250326 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250326 DATE AS OF CHANGE: 20250326 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC CENTRAL INDEX KEY: 0001484565 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 770523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 25774133 BUSINESS ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-213-8444 MAIL ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Capnia, Inc. DATE OF NAME CHANGE: 20100219 8-K 1 d833373d8k.htm 8-K 8-K SOLENO THERAPEUTICS INC false 0001484565 0001484565 2025-03-26 2025-03-26     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 26, 2025     SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   001-36593   77-0523891 (State or other jurisdiction of incorporation)   (Commission File No.)   (IRS Employer Identification Number) 100 Marine Parkway , Suite 400 Redwood City , CA 94065 (Address of principal executive offices) (650) 213-8444 (Registrant’s telephone number, including area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading symbols   Name of each exchange on which registered Common Stock, $0.001 par value   SLNO   NASDAQ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       ITEM 2.02 Results of Operations and Financial Conditions On March 26, 2025, Soleno Therapeutics, Inc. (the “Company”) issued a press release announcing that VYKAT TM XR (diazoxide choline) extended-release tablets has been approved by the U.S. Food and Drug Administration. VYKAT TM XR is indicated to treat hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. ITEM 9.01 Financial Statements and Exhibits (d) Exhibits   Exhibit No.